We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+52.01%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$3.55B
AUM Growth
+$1.23B
Cap. Flow
+$396M
Cap. Flow %
11.15%
Top 10 Hldgs %
48.38%
Holding
82
New
17
Increased
31
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$115M
2
BAX icon
Baxter International
BAX
+$84.4M
3
CERN
Cerner Corp
CERN
+$81.3M
4
AXSM icon
Axsome Therapeutics
AXSM
+$46.6M
5
TXG icon
10x Genomics
TXG
+$34.7M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$94M
2
ZBH icon
Zimmer Biomet
ZBH
+$67.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$51.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$36.8M
5
STAA icon
STAAR Surgical
STAA
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.43%
2 Materials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$352M 9.9%
16,812,491
– –
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$36.3B
$249M 7.01%
1,681,645
– –
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$201M 5.66%
3,963,120
+30,374
+0.8% +$1.49M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$182M 5.11%
7,152,918
+189,783
+3% +$4.09M
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$142M 3.99%
679,003
+15,840
+2% +$2.81M
IMVT icon
6
Immunovant
IMVT
$8.09B
$139M 3.92%
5,717,182
+1,291,076
+29% +$27.7M
AXSM icon
7
Axsome Therapeutics
AXSM
$12.4B
$136M 3.84%
1,658,316
+605,347
+57% +$46.6M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$124M 3.49%
1,087,726
+102,560
+10% +$9.95M
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$104M 2.92%
+3,995,000
New +$115M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$90.5M 2.55%
936,931
+156,033
+20% +$13M
MASI
11
DELISTED
Masimo
MASI
$88.6M 2.49%
388,776
+5,861
+2% +$1.29M
STOK icon
12
Stoke Therapeutics
STOK
$1.82B
$84.5M 2.38%
3,544,248
– –
BAX icon
13
Baxter International
BAX
$11.6B
$83.5M 2.35%
+969,370
New +$84.4M
CERN
14
DELISTED
Cerner Corp
CERN
$81.1M 2.28%
+1,182,409
New +$81.3M
NTRA icon
15
Natera
NTRA
$37.5B
$76.2M 2.14%
1,529,128
+263,003
+21% +$10.6M
TBIO
16
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$66.6M 1.87%
3,716,994
+24,570
+0.7% +$370K
RLMD icon
17
Relmada Therapeutics
RLMD
$544M
$66.3M 1.86%
1,480,852
+496,310
+50% +$21M
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
$66.1M 1.86%
1,883,257
+174,257
+10% +$6M
QTTB icon
19
Q32 Bio
QTTB
$450M
$66.1M 1.86%
241,788
-2,615
-1% -$697K
BLU
20
DELISTED
BELLUS Health Inc.
BLU
$61.5M 1.73%
5,970,230
+479,238
+9% +$4.86M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.75B
$59.7M 1.68%
3,383,208
+722,816
+27% +$9.07M
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.17B
$59.2M 1.67%
598,923
+155,198
+35% +$12.4M
TXG icon
23
10x Genomics
TXG
$5.87B
$56.8M 1.6%
636,092
+445,983
+235% +$34.7M
OYST
24
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$55.1M 1.55%
1,909,360
+939,882
+97% +$28.3M
VCEL icon
25
Vericel Corp
VCEL
$2.3B
$53.2M 1.5%
3,850,347
-610,408
-14% -$8.26M
1
2 3 4

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q2 2020 Portfolio in Review

As of Q2 2020, RTW Investments held 82 positions worth $3.55B, up 53% from $2.32B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

RTW Investments deployed $396M of net new capital in Q2 2020, opening 17 new positions and adding to 31 existing holdings. Its largest new stake was Avidity Biosciences: 3,995,000 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was STAAR Surgical, an estimated $15M trimmed.

  • RTW Investments's largest Q2 2020 buy was Avidity Biosciences: 3,995,000 shares worth $104M.
  • RTW Investments added most to Axsome Therapeutics in Q2 2020, an estimated $46.6M increase.
  • RTW Investments's biggest Q2 2020 reduction was STAAR Surgical, cutting an estimated $15M.
  • RTW Investments fully exited Bristol-Myers Squibb in Q2 2020, selling an estimated $94M.
  • RTW Investments's ten largest holdings make up 48% of its $3.55B portfolio in Q2 2020.
  • RTW Investments opened 17 new positions and closed 5 in Q2 2020.
  • RTW Investments's portfolio value rose 53% quarter-over-quarter to $3.55B.

Based on RTW Investments's 13F filing for Q2 2020, filed 14 Aug 2020.